PRV

(redirected from Priority Review Voucher)
AcronymDefinition
PRVPatent- och Registreringsverket (Swedish Patent Office)
PRVPressure Regulating/Regulator Valve
PRVProgramu Rozvoje Venkova (Czech: Rural Development Programme)
PRVPressure Reducing Valve
PRVPressure Relief Valve
PRVPseudorabies Virus
PRVPrivate
PRVPeugeot Renault Volvo
PRVPlanning Organ-at-Risk Volume (oncology)
PRVPlatte River Valley
PRVPiano Roll View (digital audio)
PRVPower Roof Ventilator
PRVPolycythemia Rubra Vera
PRVPeak Reverse Voltage
PRVPlant Replacement Value
PRVPaint Rock Valley (Alabama)
PRVPeugeot Renault Volvo (joint engine design/manufacturing)
PRVPersonnel Recovery Vehicle
PRVPermanent Resident Visa
PRVPost Residual Volume (urology)
PRVPriority Review Voucher
PRVPlate-forme de Realite Virtuelle
PRVPokemon: Ruby Version (game)
PRVPowered Room Ventilator
PRVPokemon: Red Version (game)
PRVPolyester Renforcé de Fibre de Verre (French: Reinforced Polyester Fiberglass)
PRVPearl River Valley Railroad Company
PRVPhenomena Research Victoria (Australia)
PRVProduction Representative Vehicle (US Army)
PRVPropellant Valve
PRVPackage Receipt Voucher
PRVPipe Rupture Valve
PRVPerformance Readiness Validation
PRVPeak Reverse Velocity
PRVPoly Reinforced Vinyl
References in periodicals archive ?
Target: US Food and Drug Administration Priority Review Voucher
Release date- 22082019 - Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M.
AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
Under the FDA's rare pediatric disease priority review voucher program, upon the approval of a qualifying new drug application (NDA) or biologies license application (BLA) for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a voucher that can be used to obtain priority review for a subsequent NDA or BLA.
Under the FDA's rare pediatric disease priority review voucher program, upon the approval of a qualifying new drug application (NDA) or biologics license application (BLA) for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a voucher that can be used to obtain priority review for a subsequent NDA or BLA.
It also reauthorizes the pediatric rare disease priority review voucher proram, requires drug companies to have a publicly accessible compassionate use policy for drugs treating serious or life-threatening conditions, and provides flexibility to get new antimicrobial drugs to market quickly.
The update on the prioritization follows the introduction last month of a Senate bill that would create a priority review voucher program to reward companies for developing a generic with only one competing product on the market or on the FDA's drug shortage list.
Under the FDA's Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval of a new drug application (NDA) or biologics license application (BLA) for a rare pediatric disease may be eligible for a voucher which can be redeemed to obtain priority review for a subsequent marketing application for a different product.
The priority review voucher is an expedited review granted by the Food and Drug Administration (FDA) to the developer of a treatment for neglected diseases.
Drug companies may be more willing to develop treatments for neglected diseases--including malaria, tuberculosis, and leishmanaiasis--if the European Union would adopt a "priority review voucher" reward system.
A drug maker that develops a treatment for a rare, neglected pediatric disease would receive a "priority review voucher" from the FDA that it could use to speed review of another product it wished to market, providing "a strong financial incentive for the development of treatments for otherwise neglected diseases," Sen.
Full browser ?